AAPL303.42-5.49 (-1.78%) ▼|ABBV245.10-5.84 (-2.33%) ▼|ABT107.12+1.42 (+1.34%) ▲|ACN165.76-0.16 (-0.10%) ▼|ADBE251.34+0.93 (+0.37%) ▲|AMAT518.21+10.54 (+2.08%) ▲|AMD484.64+8.49 (+1.78%) ▲|AMGN378.87-6.29 (-1.63%) ▼|AMT173.00-0.36 (-0.21%) ▼|AMZN284.02+12.44 (+4.58%) ▲|AVGO392.23+2.95 (+0.76%) ▲|AXP344.72+8.47 (+2.52%) ▲|BA233.49+17.35 (+8.03%) ▲|BAC62.48+0.53 (+0.86%) ▲|BKNG192.71-0.19 (-0.10%) ▼|BLK1,126.63+36.24 (+3.32%) ▲|BMY65.47+0.16 (+0.25%) ▲|BNY156.20-0.13 (-0.08%) ▼|BRK-B513.14+1.60 (+0.31%) ▲|C133.57+1.79 (+1.36%) ▲|CAT830.03+15.22 (+1.87%) ▲|CL89.88-1.42 (-1.56%) ▼|CMCSA24.56+0.60 (+2.50%) ▲|COF217.68+8.67 (+4.15%) ▲|COP119.16-1.32 (-1.10%) ▼|COST954.08+2.19 (+0.23%) ▲|CRM185.95+1.93 (+1.05%) ▲|CSCO115.86-0.13 (-0.11%) ▼|CVS105.37+0.94 (+0.90%) ▲|CVX193.18-3.65 (-1.85%) ▼|DE605.06+12.39 (+2.09%) ▲|DHR197.50+2.52 (+1.29%) ▲|DIS98.14+1.95 (+2.03%) ▲|DUK124.28-1.15 (-0.92%) ▼|EMR154.85+5.03 (+3.36%) ▲|FDX309.24+1.84 (+0.60%) ▲|GD382.43-0.99 (-0.26%) ▼|GE368.93+8.86 (+2.46%) ▲|GEV1,006.76+16.47 (+1.66%) ▲|GILD131.15+0.94 (+0.72%) ▲|GM87.68-1.18 (-1.33%) ▼|GOOG372.47+15.82 (+4.44%) ▲|GOOGL373.51+17.38 (+4.88%) ▲|GS1,027.06+8.68 (+0.85%) ▲|HD340.02+8.06 (+2.43%) ▲|HON246.77+3.72 (+1.53%) ▲|IBM226.31+2.66 (+1.19%) ▲|INTC91.00+0.80 (+0.89%) ▲|INTU318.39+2.32 (+0.73%) ▲|ISRG375.41+22.08 (+6.25%) ▲|JNJ254.41-1.94 (-0.76%) ▼|JPM352.64+0.85 (+0.24%) ▲|KO86.86-0.73 (-0.83%) ▼|LIN480.46+2.08 (+0.43%) ▲|LLY1,121.36-27.48 (-2.39%) ▼|LMT586.29+3.55 (+0.61%) ▲|LOW212.06+4.25 (+2.05%) ▲|LRCX294.61+1.59 (+0.54%) ▲|MA570.97-2.13 (-0.37%) ▼|MCD265.23-5.41 (-2.00%) ▼|MDLZ61.73-0.58 (-0.93%) ▼|MDT86.68+1.29 (+1.51%) ▲|META590.24+33.53 (+6.02%) ▲|MMM177.23+0.95 (+0.54%) ▲|MO68.26-0.07 (-0.10%) ▼|MRK127.77-2.43 (-1.87%) ▼|MS211.23+0.81 (+0.38%) ▲|MSFT487.65+22.93 (+4.93%) ▲|MU829.50+6.47 (+0.79%) ▲|NEE86.55-0.37 (-0.43%) ▼|NFLX73.33+1.62 (+2.26%) ▲|NKE42.64+0.93 (+2.23%) ▲|NOW114.19+2.96 (+2.66%) ▲|NVDA206.64+5.89 (+2.93%) ▲|ORCL141.85+11.98 (+9.22%) ▲|PEP139.63+0.07 (+0.05%) ▲|PFE25.03+0.02 (+0.08%) ▲|PG144.97+0.48 (+0.33%) ▲|PLTR125.65+2.59 (+2.10%) ▲|PM187.41-3.41 (-1.79%) ▼|QCOM151.57+3.96 (+2.68%) ▲|RTX216.65+1.43 (+0.66%) ▲|SBUX103.37-1.88 (-1.79%) ▼|SCHW105.87+0.63 (+0.60%) ▲|SO92.94-1.60 (-1.69%) ▼|SPG229.16-0.21 (-0.09%) ▼|T23.59+0.34 (+1.46%) ▲|TMO574.03-0.27 (-0.05%) ▼|TMUS177.09+4.38 (+2.54%) ▲|TSLA322.08+10.87 (+3.49%) ▲|TXN269.04-6.70 (-2.43%) ▼|UBER71.61+1.25 (+1.78%) ▲|UNH415.36+0.96 (+0.23%) ▲|UNP291.23-0.90 (-0.31%) ▼|UPS106.87+2.65 (+2.54%) ▲|USB63.94+0.93 (+1.48%) ▲|V365.67-0.46 (-0.13%) ▼|VZ47.36+0.55 (+1.18%) ▲|WFC87.89+1.44 (+1.67%) ▲|WMT110.71-0.49 (-0.44%) ▼|XOM155.06-0.38 (-0.24%) ▼|AAPL303.42-5.49 (-1.78%) ▼|ABBV245.10-5.84 (-2.33%) ▼|ABT107.12+1.42 (+1.34%) ▲|ACN165.76-0.16 (-0.10%) ▼|ADBE251.34+0.93 (+0.37%) ▲|AMAT518.21+10.54 (+2.08%) ▲|AMD484.64+8.49 (+1.78%) ▲|AMGN378.87-6.29 (-1.63%) ▼|AMT173.00-0.36 (-0.21%) ▼|AMZN284.02+12.44 (+4.58%) ▲|AVGO392.23+2.95 (+0.76%) ▲|AXP344.72+8.47 (+2.52%) ▲|BA233.49+17.35 (+8.03%) ▲|BAC62.48+0.53 (+0.86%) ▲|BKNG192.71-0.19 (-0.10%) ▼|BLK1,126.63+36.24 (+3.32%) ▲|BMY65.47+0.16 (+0.25%) ▲|BNY156.20-0.13 (-0.08%) ▼|BRK-B513.14+1.60 (+0.31%) ▲|C133.57+1.79 (+1.36%) ▲|CAT830.03+15.22 (+1.87%) ▲|CL89.88-1.42 (-1.56%) ▼|CMCSA24.56+0.60 (+2.50%) ▲|COF217.68+8.67 (+4.15%) ▲|COP119.16-1.32 (-1.10%) ▼|COST954.08+2.19 (+0.23%) ▲|CRM185.95+1.93 (+1.05%) ▲|CSCO115.86-0.13 (-0.11%) ▼|CVS105.37+0.94 (+0.90%) ▲|CVX193.18-3.65 (-1.85%) ▼|DE605.06+12.39 (+2.09%) ▲|DHR197.50+2.52 (+1.29%) ▲|DIS98.14+1.95 (+2.03%) ▲|DUK124.28-1.15 (-0.92%) ▼|EMR154.85+5.03 (+3.36%) ▲|FDX309.24+1.84 (+0.60%) ▲|GD382.43-0.99 (-0.26%) ▼|GE368.93+8.86 (+2.46%) ▲|GEV1,006.76+16.47 (+1.66%) ▲|GILD131.15+0.94 (+0.72%) ▲|GM87.68-1.18 (-1.33%) ▼|GOOG372.47+15.82 (+4.44%) ▲|GOOGL373.51+17.38 (+4.88%) ▲|GS1,027.06+8.68 (+0.85%) ▲|HD340.02+8.06 (+2.43%) ▲|HON246.77+3.72 (+1.53%) ▲|IBM226.31+2.66 (+1.19%) ▲|INTC91.00+0.80 (+0.89%) ▲|INTU318.39+2.32 (+0.73%) ▲|ISRG375.41+22.08 (+6.25%) ▲|JNJ254.41-1.94 (-0.76%) ▼|JPM352.64+0.85 (+0.24%) ▲|KO86.86-0.73 (-0.83%) ▼|LIN480.46+2.08 (+0.43%) ▲|LLY1,121.36-27.48 (-2.39%) ▼|LMT586.29+3.55 (+0.61%) ▲|LOW212.06+4.25 (+2.05%) ▲|LRCX294.61+1.59 (+0.54%) ▲|MA570.97-2.13 (-0.37%) ▼|MCD265.23-5.41 (-2.00%) ▼|MDLZ61.73-0.58 (-0.93%) ▼|MDT86.68+1.29 (+1.51%) ▲|META590.24+33.53 (+6.02%) ▲|MMM177.23+0.95 (+0.54%) ▲|MO68.26-0.07 (-0.10%) ▼|MRK127.77-2.43 (-1.87%) ▼|MS211.23+0.81 (+0.38%) ▲|MSFT487.65+22.93 (+4.93%) ▲|MU829.50+6.47 (+0.79%) ▲|NEE86.55-0.37 (-0.43%) ▼|NFLX73.33+1.62 (+2.26%) ▲|NKE42.64+0.93 (+2.23%) ▲|NOW114.19+2.96 (+2.66%) ▲|NVDA206.64+5.89 (+2.93%) ▲|ORCL141.85+11.98 (+9.22%) ▲|PEP139.63+0.07 (+0.05%) ▲|PFE25.03+0.02 (+0.08%) ▲|PG144.97+0.48 (+0.33%) ▲|PLTR125.65+2.59 (+2.10%) ▲|PM187.41-3.41 (-1.79%) ▼|QCOM151.57+3.96 (+2.68%) ▲|RTX216.65+1.43 (+0.66%) ▲|SBUX103.37-1.88 (-1.79%) ▼|SCHW105.87+0.63 (+0.60%) ▲|SO92.94-1.60 (-1.69%) ▼|SPG229.16-0.21 (-0.09%) ▼|T23.59+0.34 (+1.46%) ▲|TMO574.03-0.27 (-0.05%) ▼|TMUS177.09+4.38 (+2.54%) ▲|TSLA322.08+10.87 (+3.49%) ▲|TXN269.04-6.70 (-2.43%) ▼|UBER71.61+1.25 (+1.78%) ▲|UNH415.36+0.96 (+0.23%) ▲|UNP291.23-0.90 (-0.31%) ▼|UPS106.87+2.65 (+2.54%) ▲|USB63.94+0.93 (+1.48%) ▲|V365.67-0.46 (-0.13%) ▼|VZ47.36+0.55 (+1.18%) ▲|WFC87.89+1.44 (+1.67%) ▲|WMT110.71-0.49 (-0.44%) ▼|XOM155.06-0.38 (-0.24%) ▼|
23.7 C
New York
Tuesday, August 4, 2026

Tag: cognitive decline

newssourceFORcompanyinformationcontent1releasesmarket

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of...

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of...

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of...

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

GENEVA, June 27, 2026 /CNW/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of...

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagementFindings support continued...

Alzheimer’s & Dementia Awareness Launches Nationwide

National Campaign Explores Advances in Early Detection, Research, Caregiving, and Brain HealthNEW YORK, June 17, 2026 /PRNewswire/ -- Mediaplanet today announces the launch of...

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~

Prioritize Brain Health with a Peanut-Packed Menu

A healthy brain goes beyond reading exercises and completing puzzles – it extends to the kitchen, too.

4 Everyday Ways to Keep Your Brain Sharp

MISSION, Kan., Aug. 11, 2025 /PRNewswire/ -- (Family Features) Staying in shape goes beyond physical fitness – keeping your brain health top of mind is...

Synaptigen Introduced as Natural Brain Support Option for Aging Adults in 2025

Clinically-Inspired Daily Formula Highlights Cognitive Clarity, Focus, and Mental Energy for Adults Over 50 
Clinically-Inspired Daily Formula Highlights Cognitive Clarity, Focus, and Mental Energy for Adults Over 50

ChatGPT Gets Rowdy, World Keeps Spinning

On today's rundown, we’ve got the usual suspects in tech hype: Meta throwing its checkbook at AI talent, the brain drain from pandemic stress,...

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCognitive decline

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers